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A Commentary on
Understanding the Impact of Infection, Inflammation, and Their Persistence in the Pathogenesis 
of Bronchopulmonary Dysplasia
by Balany J, Bhandari V. Front Med (2015) 2:90. doi:10.3389/fmed.2015.00090
As Drs. Balany and Bhandari (1) point out in their recent review, despite the development of sur-
factant therapy, and new forms of non-invasive ventilation, bronchopulmonary dysplasia (BPD) 
remains the most common chronic respiratory disease in newborns/infants. The authors point 
out the key drivers of disease including infection, barotrauma, hyperoxia, and inflammation and 
highlight the potential role that inflammation plays in driving the disease. Lung inflammation can 
be triggered by activation of the innate immune system and this can be triggered by cell surface or 
cytoplasmic receptors that fall into the three key categories—toll-like receptors (TLRs), Nod-like 
receptors (NLRs), and c-type lectin receptors (CLRs). TLRs 1, 2, 4, and 6 are surface receptors 
that recognize both exogenous stimuli such as lipopeptides or endotoxin (2) and endogenous 
ligands such as Hsp70 or oxidized phospholipids (3). Thus, inflammation in BPD could be driven 
by ligands from invading pathogens in an intubated patient or endogenous ligands that could be 
released during hyperoxia. One could envision that the therapeutic approach may be different given 
the proximal driver of inflammation. Thus, it is important to not only to characterize the type of 
inflammation but we need a keen understanding of what initiated the response. NLRs are cyto-
plasmic receptors and have several ligands including muramyl dipeptide (2). These receptors play 
a key role in activation of the inflammasome which is an intracellular protein structure that results 
in caspase-1 mediated cleavage of proIL-1β or pro-IL-18 into mature secreted proteins. By con-
trast, other IL-1 family members such as IL-1α or IL-33 can be released and be biologically active 
independent of caspase-1-mediated cleavage. This pathway is an active area of drug development 
as there is strong genetic evidence of IL-33 in asthma (4, 5). For ligands that bind IL-1R1, IL-1β, 
and IL-1α, Anakinra has been FDA approved for the treatment of rheumatoid arthritis and for the 
treatment of neonatal-onset multisystem inflammatory disease (5). Given that overexpression of 
IL-1β results in decreased alveolarization (6), this may be a viable target. However, this pathway 
is also critical for host immunity to several pathogens including influenza (7) and Staphylococcus 
aureus infection (8), so one would need to proceed with caution and likely exclude patients with 
active infection. CLRs recognize carbohydrate ligands such as mannans and glucans and drive 
inflammation but also can be involved in resolution of inflammation as well (9).
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As Drs. Balany and Bhandari state in their review (1), 
cytokines have been extensively evaluated in BPD including IL-1, 
IL-6, TNF, and IL-10. Moreover the CXCR2 ligands, CXCL1, and 
CXCL8 have also been found to be elevated in BPD. In preclinical 
models, CXCR2 antagonism appears to improve lung histology 
(10). CXCR2 antagonists have been studied in human clinical 
trials in cystic fibrosis and COPD. A recent phase 2 study showed 
an increased in FEV1 in COPD (11), and another trial showed 
reduced inflammation in sputum biomarkers in CF (12). Thus, 
this may be an approach in BPD. In the adult lung, CXCL8 can 
be made by both alveolar and tissue macrophages as well as the 
lung epithelium. It has been recently show in neonates that γδ 
T-cells are a major source of CXCL8 (13) and thus as the sources 
of CXCL8 may be unique in the neonatal lung—this will need to 
be taken into consideration for rational drug approaches.
Finally is the issue of resolution of inflammation. Namely, 
is BPD due to a failure to resolve inflammation? To this end, a 
critical area of needed research in this regard is the role of lipid 
mediators such as resolvins and lipoxins in BPD (14). Lipoxin 
A4 has been shown to be reduced in chronic neutrophilic 
lung inflammation in CF (15). Thus, in addition to cytokine 
measurement, there needs to be more research in assaying 
both pro-inflammatory and pro-resolving lipid mediators in 
the lungs of BPD subjects to determine if this may also be a 
target for therapeutic intervention. Moreover, we need more 
basic understanding of how gestational age and lung maturity 
affect the inflammatory response in the lung—both in terms of 
intitiating a response and in it’s resolution.
In conclusion, BPD is clearly a disease associated with airway 
inflammation with likely a complex series of initiators. However, 
defining inflammation—using unbiased omic approaches 
(proteomics and lipidomics) as well as replication studies in well-
characterized patient cohorts may improve our understanding of 
the potential role of inflammation in disease pathogenesis and 
open up new avenues of therapeutic intervention.
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